NPM1 and acute myeloid leukemia: Ongoing trials like VIALE M are evaluating the role of maintenance with oral azacitidine and venetoclax in secondary AML or high-risk myelodysplastic syndromes, but its specific applicability in NPM1-mutated patients remains to be clarified [25].